Right? So it was really good news. We liked it very much. I'm sure the, this video is still available on ABC News, a website, so you can, you can search. Alright then about HPV is done then. Um, this is about bacterias infection bacterias that acquired, uh, resistance to antibiotics, as I mentioned, that is serious, but it is expected that those bacteria is going to get a resistance to any kinds of available antibiotics. We have, like ten different kinds, different, like a different types of antibiotics available in the market. But, um, once such a bacteria happens arises, then we have really no way to treat such a bacterial infection. It is called super bugs, right? Super bugs is expected to cure more than cancer by the year 2050. So currently this is a number of deaths a by such a bacterial infection. Only 700,000 are here. This is a number of deaths by cancer. But this a was such a bacteria super bug is, is, uh, emerges then, uh, the number of deaths is expected more than cancer. So this is a really fact it's happening. So, uh, we just started evaluating ACC on multi-drug resistance bacterias. So that's for the future. And of course we are expecting AHCC effective because AHCC is not fighting against those bacteria or viruses directory. This is just inducing our natural defense mechanism, right?
Okay. So once we have a good study about this multidrug resistance, a bacteria that's going to be, uh, very exciting and of course to be presented at our Congress. Okay, now going to the oncology field. So oncology, cancer, I mentioned those abnormal cells are the supposed to be the target of our immunity, right? Then, um, at the same time, uh, in cancer patients, it is known that, uh, their immunity is at a really low profile kind of compromised all the time. That is a situation, and this was an old study, but it is one of the longest wide studies we had, uh, for AHCC. The subjects were, uh, hepatocellular carcinoma. It's a type of liver cancer and, but the, those liver cancer patients, they were already, uh, they already underwent the resection, the surgery of the, those original cancer. So they were cancer free at the time when they were, uh, recruited to the study.
So there was nothing the doctors and patients could do, but, uh, we just say put, put them in a, a prospective cohort. Two, two groups. So one is a control group without AHCC. Uh, second group is with a AHCC at the therapeutic process. So in AHCC group, they took, kept taking a AHCC every day, three rounds of a AHCC every day for over nine years. Then, um, we, we looked at their survival. Of course, it started from 100% and after nine years, this is a control group. It was about 25% of survival. This is a, in accordance with the global average for this type of he CE carcinoma. And in AHCC group, the survival rate was 50% after nine years, especially, there was no death after six years. Right? So they, they turned to be really, uh, cancer free. Yeah, that moment. So the, the rate, there was a statistics, there was a statistic of significance between two groups. So that was fantastic. But this is again explained by the immunity immune intervention and similar types of survival rate increase was seen. This was a liver type cancer. Uh, similar, a similar type of results were available, uh, in gastric cancer and colon cancer and lung cancer. So for the AHCC is not selective for cancer types basically.
And also for cancer treatment, uh, we have surgery, chemotherapy, and radiotherapy. And in late radiotherapy and chemotherapy, we always expect, uh, certain level of side effects. So AHCC is well evaluated on such a side effects. In this case, this is, uh, a report and this, this was presented from the doctors or the University of Tokyo, uh, a few years ago. A few years ago, they, they tried AHCC in the breast cancer patients undergoing, uh, those certain anthracycline and tax based, uh, chemotherapy. So of course they expected, uh, certain level of side effects. So the study is published, this is against therapeutic dosage, three grams per day. And they, they measured, evaluated those blood chemistry and also evaluated the side effects adverse events. So in the blood chemistry, they saw a significant improvement by AHCC on the number of neutrophil. So in a control group, just by chemicallly, their number of neutrophil got a really significant down.
But, uh, in a the AHCC group, they could maintain. Yeah. So there was a significance between two groups in the number of neutrophil. And moreover, there was a significant difference in the number of usage of GCSF. GCSF is a injection drug Doctors use to control the side effects. So doctors use such a injection drug when, when doctors sees, uh, serious symptoms of side effects in the patient, and somehow a label is gone. But this is a control group and this is AHCC. And AHCC, they could, doctors could really sign significantly reduce the number of uses of such drug. So that's, uh, economically good as well. And that is a scientifically interpreted as this way. So GCSF is a granulocyte colony-stimulating factor, which is actually, we naturally produce in our body by neutrophil. Neutrophil produces GCSF in our body. But, uh, in a h c group, they could maintain the number of neutrophil. So they didn't need, you know, additional injection of GCSF. That is all.